Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: A meta-analysis

2011 ◽  
Vol 65 (12) ◽  
pp. 1313-1320 ◽  
Author(s):  
Y.-X. Luo ◽  
D.-K. Chen ◽  
S.-X. Song ◽  
L. Wang ◽  
J.-P. Wang
Keyword(s):  
Colorectal Cancer ◽  
Meta Analysis ◽  
Aberrant Methylation ◽  
Diagnostic Biomarkers ◽  
Stool Samples

scholarly journals Novel Diagnostic Biomarkers in Colorectal Cancer

2022 ◽  
Vol 23 (2) ◽  
pp. 852
Author(s):  
Aneta L. Zygulska ◽  
Piotr Pierzchalski
Keyword(s):  
Colorectal Cancer ◽  
Somatic Mutations ◽  
Tumor Tissue ◽  
Locally Advanced ◽  
Survival Rates ◽  
High Sensitivity ◽  
Diagnostic Biomarkers ◽  
Blood Tests ◽  
Stool Samples ◽  
Endoscopic Methods

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.

scholarly journals Faecal Diagnostic Biomarkers for Colorectal Cancer

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5568
Author(s):  
Andrea Cruz ◽  
Carla M. Carvalho ◽  
Alexandra Cunha ◽  
Anais Crespo ◽  
Águeda Iglesias ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Progression ◽  
Occult Blood ◽  
Diagnostic Value ◽  
Necrosis Factor Alpha ◽  
Diagnostic Biomarkers ◽  
Advanced Stages ◽  
Immunochemical Test ◽  
Stool Samples ◽  
Advanced Adenomas

Background: Colorectal cancer (CRC) is a major cause of cancer-related death worldwide. Cancer progression, including invasion and metastasis, is a major cause of death among CRC patients. Current methods for CRC screening commonly consist of a combination of faecal immunochemical test (FIT) for stool occult blood detection and invasive procedures such as colonoscopy. Considering the slow progression of CRC, and that symptoms usually emerge at advanced stages, its early diagnostic can limit cancer’s spread and provide a successful treatment. Biomarkers have a high potential for the diagnosis of CRC in either blood or stool samples. Methods: In this study, we analysed the diagnostic value of six different biomarkers in stool samples of patients with CRC, advanced adenomas, other lesions and healthy individuals. We have also assessed the overall performance of the combination of these biomarkers for CRC detection. Results: The results indicate that haemoglobin (Hb) and M2-pyruvate kinase (M2-PK) levels were increased in CRC patients in comparison to the controls. Conversely, the concentrations of matrix metalloproteinase (MMP)-2, MMP-9, and tumour necrosis factor-alpha (TNF-α) were not significantly different between the tested groups. Conclusion: The combination of FIT-Hb with the M2-PK levels increased the specificity or sensitivity for CRC detection and thus present potential as faecal diagnostic biomarkers for CRC.

scholarly journals Aberrant methylation patterns in colorectal cancer: a meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (8) ◽  
pp. 12820-12830 ◽  
Author(s):  
Danielle Fernandes Durso ◽  
Maria Giulia Bacalini ◽  
Ítalo Faria do Valle ◽  
Chiara Pirazzini ◽  
Massimiliano Bonafé ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Meta Analysis ◽  
Aberrant Methylation ◽  
Methylation Patterns

scholarly journals Systems biomedicine of primary and metastatic colorectal cancer reveals potential therapeutic targets

2020 ◽  
Author(s):  
Mehran Piran ◽  
Mehrdad Piran ◽  
Neda Sepahi ◽  
Ali Ghanbariasad ◽  
Amir Rahimi
Keyword(s):  
Colorectal Cancer ◽  
Cancer Progression ◽  
Molecular Mechanisms ◽  
Epithelial To Mesenchymal Transition ◽  
Meta Analysis ◽  
Ppi Network ◽  
Diagnostic Biomarkers ◽  
Mesenchymal Transition ◽  
Protein Protein Interaction ◽  
Hypoxic Conditions

AbstractColorectal cancer (CRC) is one of the major causes of cancer deaths across the world. Patients survival time at time of diagnosis depends largely on stage of the tumor. Therefore, understanding the molecular mechanisms promoting cancer progression from early stages to high-grade stages is essential for implementing therapeutic approaches. To this end, we performed a unique meta-analysis flowchart by identifying differentially expressed genes (DEGs) between normal, primary and metastatic samples in some test datasets. DEGs were employed to construct a protein-protein interaction (PPI) network. Then, a smaller network containing 39 DEGs were extracted from the PPI network whose nodes expression induction or suppression alone or in combination with each other would inhibit tumor progression or metastasis. A number of these DEGs were then verified by gene expression profiling, survival analysis and a number of validation datasets from different genomic repositories. They were involved in cell proliferation, energy production under hypoxic conditions, epithelial to mesenchymal transition (EMT) and angiogenesis. Multiple combination targeting of these DEGs were proposed to have high potential in preventing cancer progression. Some genes were also presented as diagnostic biomarkers for colorectal cancer. Finally, TMEM131, DARS and SORD genes were identified in this study which had never been associated with any kind of cancer neither as a biomarker nor curative target.

Sign in / Sign up

Export Citation Format

Share Document